Immix Biopharma, Inc. (IMMX)
| Market Cap | 719.60M +788.3% |
| Revenue (ttm) | n/a |
| Net Income | -39.92M |
| EPS | -0.83 |
| Shares Out | 82.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,314,377 |
| Open | 8.51 |
| Previous Close | 8.51 |
| Day's Range | 8.45 - 8.91 |
| 52-Week Range | 2.48 - 15.10 |
| Beta | 0.24 |
| Analysts | Strong Buy |
| Price Target | 24.30 (+179.95%) |
| Est. Earnings | Nov 6, 2026 |
About IMMX
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for IMMX stock is "Strong Buy." The 12-month stock price target is $24.3, which is an increase of 179.95% from the latest price.
News
Immix Biopharma Slides: Investor presentation
Immix Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on October 7, 2026.
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present at the...
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the cl...
Immix Biopharma price target raised to $30 from $27 at BofA
BofA raised the firm’s price target on Immix Biopharma (IMMX) to $30 from $27 and keeps a Buy rating on the shares. Following interim data, the firm increased its view…
Immix Biopharma Transcript: Study result
NXC-201 produced 40 complete responses among 45 patients; including MRD-negative patients, 44/45 were in CR or MRD-negative, with further CR conversions anticipated. Median CRS lasted one day, with no high-grade CRS or neurotoxicity reported.
Immix Biopharma Press release: Study result
Immix Biopharma issued a press release on September 29, 2026, disclosing material business information to investors.
Immix announces 89% CR rate in interim update across NEXICART-2 patients
Immix Biopharma (IMMX) announced positive results of an 89% complete response, CR, rate in an interim update across all forty-five NEXICART-2 patients, advancing NXC-201 as a potential best-in-class t...
Immix Biopharma prices 11.36M share registered offering at $11.00
Immix Biopharma (IMMX) announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds…
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricin...
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
– 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) –
Immix Biopharma price target raised to $26 from $15 at Mizuho
Mizuho raised the firm’s price target on Immix Biopharma (IMMX) to $26 from $15 and keeps an Outperform rating on the shares ahead of next Phase 2 NEXICART-2 study readout…
Immix Biopharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
NXC-201, a novel CAR T therapy for AL amyloidosis, demonstrates rapid, deep responses and a favorable safety profile, with regulatory designations supporting accelerated review. A pivotal readout and BLA submission are expected, and a Phase III frontline trial is underway.
Immix Biopharma Slides: Corporate presentation
Immix Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
Immix Biopharma price target lowered to $19 from $20 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Immix Biopharma (IMMX) to $19 from $20 and keeps an Overweight rating on the shares. The firm updated its model to reflect…
Immix Biopharma Slides: Corporate presentation
Immix Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Immix Biopharma price target raised to $25 from $20 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Immix Biopharma (IMMX) to $25 from $20 and keeps a Buy rating on the shares. post the Q2 report.
Immix Biopharma Quarterly report: Q2 2026
Immix Biopharma has published its Q2 2026 quarterly earnings report on August 7, 2026.
IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $IMMX--IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law.
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
LOS ANGELES, CA, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that ...
Immix Biopharma initiated with a Buy at Needham
Needham initiated coverage of Immix Biopharma (IMMX) with a Buy rating and $21 price target Immix’s lead agent, NXC-201, has shown “compelling” early efficacy and safety, says the analyst, who…
Immix Biopharma Investigated by the Portnoy Law Firm
LOS ANGELES, July 21, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Immix Biopharma , (“ Immix " or the "Company") ( NASDAQ : IMMX) investors that the firm has initiated an investigation into...
Immix Biopharma announces termination of CMO Richard Graydon
In a regulatory filing, Immix Biopharma (IMMX) announced that as of July 17, Richard Graydon has been terminated and is no longer with the company for reasons unrelated to his…
Wanted fugitive secretly working at Immix as CMO, STAT reports
A fugitive former doctor convicted of sexual assault was arrested after allegedly living under an alias as a biotech executive, including serving as chief medical officer at Immix Biopharma (IMMX)…
Immix Biopharma Slides: Corporate presentation
Immix Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on July 3, 2026.
Immix Biopharma initiated with a Buy at BofA
BofA initiated coverage of Immix Biopharma (IMMX) with a Buy rating and $27 price target Early data on NXC-201 shows about 95% complete response and rapid minimal residual disease in…